Last updated on May 2018

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)


Brief description of study

The purpose of this study is to evaluate the safety and efficacy of two INCB050465 treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

Clinical Study Identifier: NCT03144674

Find a site near you

Start Over

Torrance Health Association

Redondo Beach, CA United States
  Connect »

Sansum Clinical

Santa Barbara, CA United States
  Connect »

Valley View Hospital

Glenwood Springs, CO United States
  Connect »

Advanced Pharma - Miami

Located in: Miami, FL USA
  Connect »

Asclepes Research Centers

Spring Hill, FL United States
  Connect »

Clinical Trials of SWLA, LLC

Lake Charles, LA United States
  Connect »

Henry Ford Hospital

Detroit, MI United States
  Connect »

Clinical Research Alliance

Lake Success, NY United States
  Connect »

White Plains Hospital

White Plains, NY United States
  Connect »

Renovatio Clinical

Houston, TX United States
  Connect »

St. Mary's Medical Center

Santa Barbara, CA United States
  Connect »

Mission Hope Cancer Center

Santa Maria, CA United States
  Connect »

Icon Cancer Care

South Brisbane, Australia
  Connect »

Gettysburg Cancer Center

Gettysburg, PA United States
  Connect »